Free Trial

Surgery Partners, Inc. (NASDAQ:SGRY) Given Average Rating of "Moderate Buy" by Analysts

Surgery Partners logo with Medical background

Surgery Partners, Inc. (NASDAQ:SGRY - Get Free Report) has earned an average rating of "Moderate Buy" from the ten ratings firms that are presently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $33.56.

SGRY has been the topic of a number of analyst reports. Royal Bank Of Canada reiterated an "outperform" rating and issued a $35.00 price target on shares of Surgery Partners in a research report on Tuesday, March 25th. Macquarie lowered their target price on shares of Surgery Partners from $34.00 to $33.00 and set an "outperform" rating on the stock in a report on Tuesday, March 11th. Barclays cut their price target on shares of Surgery Partners from $25.00 to $24.00 and set an "equal weight" rating for the company in a report on Tuesday, May 27th. Finally, Benchmark reaffirmed a "buy" rating and set a $35.00 price objective on shares of Surgery Partners in a research note on Monday, April 21st.

Read Our Latest Stock Analysis on SGRY

Surgery Partners Stock Performance

Surgery Partners stock traded down $0.53 on Wednesday, hitting $22.02. The company's stock had a trading volume of 2,977,090 shares, compared to its average volume of 1,369,444. Surgery Partners has a one year low of $18.87 and a one year high of $33.97. The firm has a market cap of $2.82 billion, a P/E ratio of -14.39 and a beta of 1.90. The company has a quick ratio of 1.73, a current ratio of 1.89 and a debt-to-equity ratio of 1.09. The company has a fifty day moving average price of $22.46 and a 200-day moving average price of $22.68.

Surgery Partners (NASDAQ:SGRY - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported $0.04 earnings per share for the quarter, missing analysts' consensus estimates of $0.08 by ($0.04). The business had revenue of $776.00 million during the quarter, compared to the consensus estimate of $777.77 million. Surgery Partners had a negative net margin of 6.10% and a positive return on equity of 2.41%. The business's revenue was up 8.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.10 EPS. On average, equities analysts anticipate that Surgery Partners will post 0.67 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Principal Financial Group Inc. raised its position in shares of Surgery Partners by 8.8% during the fourth quarter. Principal Financial Group Inc. now owns 49,549 shares of the company's stock worth $1,049,000 after acquiring an additional 3,997 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in Surgery Partners by 17.7% during the 4th quarter. Bank of New York Mellon Corp now owns 340,776 shares of the company's stock worth $7,214,000 after purchasing an additional 51,187 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Surgery Partners by 8.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 834,417 shares of the company's stock valued at $17,665,000 after purchasing an additional 61,671 shares during the period. Raymond James Financial Inc. bought a new position in shares of Surgery Partners in the 4th quarter valued at about $10,130,000. Finally, First Eagle Investment Management LLC grew its position in shares of Surgery Partners by 17.3% during the 4th quarter. First Eagle Investment Management LLC now owns 292,278 shares of the company's stock worth $6,188,000 after buying an additional 43,100 shares during the period.

Surgery Partners Company Profile

(Get Free Report

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.

Recommended Stories

Analyst Recommendations for Surgery Partners (NASDAQ:SGRY)

Should You Invest $1,000 in Surgery Partners Right Now?

Before you consider Surgery Partners, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Surgery Partners wasn't on the list.

While Surgery Partners currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth
5 Stocks to BUY NOW in July 2025
3 Defense Stocks Under $10 With Massive Upside

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines